BIONIC EYE TRIAL RESULTS SHOW SUBSTANTIAL VISION IMPROVEMENTS OVER TWO AND A HALF YEARS Blind participants with retinitis pigmentosa able to locate doorways, avoid obstacles
SEGMENT
Filmed in Melbourne and Sydney | February 2025
Released on Retinitis Pigmentosa Awareness Month
INTERVIEWED
Professor James Fallon,
Chief Technology Officer Bionics Institute &
Head of the Medical Bionics Department, University of Melbourne
Associate Professor Penelope Allen,
Head of Bionic Eye Project & Principal Investigator,
Centre for Eye Research Australia (CERA) &
Vitreoretinal Surgeon,
Royal Victorian Eye and Ear Hospital
Dr Ash Attia
Chief Executive Officer & Managing Director
Bionic Vision Technologies
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Detailed outcomes from the trial, led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, were published in Ophthalmology Science.
The findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
Retinitis pigmentosa is an inherited retinal disease which affects about two million people worldwide and is one of the leading causes of vision loss in working-age people.
The bionic eye comprises an electrode array, designed by the Bionics Institute and the Centre for Eye Research Australia, that is surgically implanted behind the eye. The electrode receives signals from a video camera mounted on glasses, which stimulate the patient’s retina.
Credit: Retinitis pigmentosa fact sheet from Retina Australia
You Might also like
-
Raising awareness, engagement and inclusion of Allied Health
Anita Hobson-Powell holds the position of Chief Allied Health Officer for the Australian Government within the Department of Health and Aged Care. With a background as an exercise physiologist and extensive experience leading allied health professional associations*, she has been entrusted with three main priorities. First, she aims to raise awareness about the significance of allied health professionals and their role in the healthcare system. This involves ensuring that decision makers and individuals engaging with health services understand the contributions of allied health professionals.
-
Research finds many practitioners feel underprepared to navigate men’s distress
Movember’s Men in Mind expands nationally to equip mental health professionals with the tools to better connect with men before they reach crisis point. Research conducted by the Men’s Health Research team at Movember has found men account for three in every four suicide deaths in Australia, and more than 50% had sought help in the year before they died.
-
Strategic research investments for health and prosperity
The CEO of Research Australia, Nadia Levin spoke with Australian Health Journal about the following:
– Current medical research and development landscape in Australia
– Investment required to support the Health and Medical Research and Innovation pipeline
– The National Medical Products Industry Plan and its impact on the Australian economy
– The Health and Medical Research WorkforceIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.